High Potency Active Pharmaceutical Ingredients Market Is Fast-Acting Drug That Has Improved Effectiveness of Treatment
High potency active pharmaceutical ingredients are molecules
widely used in the production of hormonal drugs which are used for the treatment
of breast cancer. It is also used in the central nervous system drugs,
cardiovascular drugs, and musculoskeletal drugs. Moreover, recently they have
been also gaining demand in the gynecology & cosmetics industry. These
drugs are segmented into innovative and generic.
The growing prevalence of cancer is predominantly fueling
the growth of the high potency active pharmaceutical ingredients market. The
increasing number of the pharmaceutical industry coupled with the growing
investment in the research and development activities conducted by the
pharmaceutical industry is again contributing to the market growth. Moreover,
increasing use of high potency active pharmaceutical ingredients as
antibody-drug conjugates as it is one of the most important and effective
treatments for cancer is also projected to augment the market growth. It is
also used to treat glaucoma which is further anticipated to foster the growth
of the high potency active pharmaceutical ingredients market.
From the geographical point of view, North America is
expected to gain significant growth over the forecast period and this is
attributed to the high prevalence of the chronic disease in the region.
According to the National Health Council, chronic diseases affect around 133
million Americans, representing more than 40% of the total population of this
country. About half of all adults have a chronic condition, and approximately 8
percent of children ages 5 to 17 were reported by their parents to have limited
activities due to at least one chronic disease or disability.
Key Developments:
1. In September 2020, Seqens, a worldwide manufacturer of
pharmaceutical ingredients, has launched a specialized production unit at its
site in Villeneuve-La-Garenne, France. The $ 35 million (€ 30 million) facility
will tackle the development and production of high potency active
pharmaceutical ingredients (HPAPI).
2. In February 2020, Sanofi announced its plans to create a
major European company dedicated to the production and marketing to third
parties of active pharmaceutical ingredients (API), which are the essential
molecules responsible for the beneficial effects used in the composition of any
drug.
3. In June 2019, Lonza has invested in two multi-purpose
production lines for HPAPI manufacturing at its Visp site in Switzerland. Lonza
has also optimised capacity to improve its flexibility in existing production
lines, supporting shorter time-to-market and accelerated approval timelines for
partners.
Comments
Post a Comment